Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04927481 | A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer | terminated | Phase 2 | 28 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT04995575 | Dissecting the Pathways of Therapy Resistance in Early Breast Cancer(MINDACTRelapse) | terminated | — | 31 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK |
| 2 |
| Feb 22, 2024 |
| clinicaltrials |
| NCT04461600 | A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer(TENACITY) | terminated | Phase 2 | 18 | Ayala Pharmaceuticals, Inc,INDUSTRY | 5 | Feb 12, 2024 | clinicaltrials |
| NCT05236387 | Evaluating the Ability of 99mTc-Tilmanocept to Identify Clipped Nodes in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy and Sentinel Lymph Node Dissection | terminated | — | 14 | Johns Hopkins UniversityOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT02771795 | A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC | terminated | — | 538 | Samsung Bioepis Co., Ltd.INDUSTRY | 7 | Feb 2, 2024 | clinicaltrials |
| NCT00984490 | Metformin Hydrochloride in Treating Women With Stage I or Stage II Breast Cancer That Can Be Removed By Surgery | terminated | N/A | 5 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT01956552 | Changes in Phenotype and Genotype of Breast Cancers During the Metastatic Process and Optimization of Therapeutic Targeting (ESOPE) | terminated | N/A | 130 | Institut CurieOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT02768337 | Cambridge Brain Mets Trial 1(CamBMT1) | terminated | Phase 1 / Phase 2 | 26 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT04869943 | Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer(ARTEST) | terminated | Phase 3 | 52 | Veru Inc.INDUSTRY | 4 | Jan 26, 2024 | clinicaltrials |
| NCT05489679 | A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer | terminated | Phase 1 | 6 | Accutar Biotechnology IncINDUSTRY | 1 | Jan 25, 2024 | clinicaltrials |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | terminated | Phase 1 | 16 | Kite, A Gilead CompanyINDUSTRY | 1 | Jan 24, 2024 | clinicaltrials |
| NCT04947917 | Axillary Lymph Node Tattoo Marking Study | terminated | N/A | 10 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT03970967 | Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases | terminated | N/A | 1 | Alpha Tau Medical LTD.INDUSTRY | 1 | Jan 18, 2024 | clinicaltrials |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | terminated | Phase 1 / Phase 2 | 79 | Cellestia Biotech AGINDUSTRY | 6 | Jan 16, 2024 | clinicaltrials |
| NCT03992131 | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) | terminated | Phase 1 / Phase 2 | 25 | pharmaand GmbHINDUSTRY | 1 | Jan 16, 2024 | clinicaltrials |
| NCT02823262 | A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older | terminated | N/A | 65 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT03149549 | PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 99 | CytomX TherapeuticsINDUSTRY | 4 | Jan 5, 2024 | clinicaltrials |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | terminated | Phase 1 | 87 | Atreca, Inc.INDUSTRY | 1 | Dec 29, 2023 | clinicaltrials |
| NCT03480659 | Detection of Breast Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC | terminated | — | 165 | HKGepitherapeuticsINDUSTRY | 1 | Dec 21, 2023 | clinicaltrials |
| NCT05932667 | Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer(DEMETER) | terminated | Phase 2 | 1 | Institut CurieOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT04714619 | CB-103 Plus NSAI In Luminal Advanced Breast Cancer(CAILA) | terminated | Phase 2 | 2 | MedSIROTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT05363605 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 6 | Fusion Pharmaceuticals Inc.INDUSTRY | 2 | Dec 19, 2023 | clinicaltrials |
| NCT02378558 | A Trial of a New Magnetic Breast Marking Clip | terminated | N/A | 3 | Antonios LikourezosOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT00679029 | Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer | terminated | Phase 2 | 15 | University of NebraskaOTHER | 1 | Dec 11, 2023 | clinicaltrials |
| NCT06161792 | Evaluate RCN3028 in Treatment of Drug-Induced VMS in Breast Cancer(VMS) | terminated | Phase 2 | 10 | Yung Shin Pharm. Ind. Co., Ltd.INDUSTRY | 1 | Dec 8, 2023 | clinicaltrials |
| NCT00869804 | Heading Off Peripheral Neuropathy With Exercise(HOPE) | terminated | N/A | 19 | University of NebraskaOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT02642094 | Aging Mammary Stem Cells and Breast Cancer Prevention | terminated | Phase 2 | 58 | LuZhe SunOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT04690855 | A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer(TARA) | terminated | Phase 2 | 1 | Mylin A. Torres, MDOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT03861403 | A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors | terminated | Phase 1 | 10 | Leap Therapeutics, Inc.INDUSTRY | 1 | Nov 30, 2023 | clinicaltrials |
| NCT04777786 | Early Rehabilitation for Breast Cancer - A Randomized Control Trial | terminated | N/A | 3 | University of South CarolinaOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT02963363 | Adapted Physical Activity for Breast Cancer HER2 Positive Patient(APACAN2) | terminated | N/A | 36 | Centre Jean PerrinOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT01990352 | Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy | terminated | Phase 2 | 24 | University of ArizonaOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT01931709 | FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer | terminated | N/A | 35 | University of WashingtonOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT01901562 | Feasibility and Therapeutic Efficacy of Ductoscopic Papilloma Extraction in Patients With Pathologic Nipple Discharge | terminated | N/A | 9 | Montefiore Medical CenterOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT02127073 | Pilot Study of Oxytocin and microRNA Identification in NAF, Serum, and Tissue in Women With Breast Cancer | terminated | Phase 2 | 8 | Montefiore Medical CenterOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT04149522 | Evaluation of Mepitel Film® in Preventing Epidermitis in Patients Receiving Radiation Therapy for Breast Cancer | terminated | Phase 2 | 40 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)OTHER | 1 | Nov 8, 2023 | clinicaltrials |
| NCT03931655 | Photoacoustic Lymph Node Imaging | terminated | — | 1 | Geoff LukeOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT04932031 | Risk Prediction of Taxane Chemotherapy-Induced Peripheral Neuropathy(SENSE) | terminated | — | 123 | Sapere BioINDUSTRY | 1 | Nov 3, 2023 | clinicaltrials |
| NCT03786094 | Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer(FORTRESS) | terminated | Phase 3 | 432 | Spexis AGINDUSTRY | 13 | Nov 1, 2023 | clinicaltrials |
| NCT00019643 | Factors Affecting Weight Gain in Women Receiving Adjuvant Chemotherapy for Breast Cancer | terminated | — | 26 | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 31, 2023 | clinicaltrials |
| NCT02254031 | Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer | terminated | Phase 1 | 8 | Boehringer IngelheimINDUSTRY | 0 | Oct 24, 2023 | clinicaltrials |
| NCT02626377 | Multicenter Prospective Cohort of Informal Caregivers in Burgundy and Franche-Comté(ICE) | terminated | N/A | 186 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT03623490 | Optimizing the Management of Patients With Oral Therapy(IPAC) | terminated | N/A | 101 | Centre Georges Francois LeclercOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT05414123 | A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide(FORESEE) | terminated | — | 40 | Biocept, Inc.INDUSTRY | 1 | Oct 16, 2023 | clinicaltrials |
| NCT04562233 | Breast Cancer and Resistance Exercise Program(B-REP) | terminated | N/A | 56 | Rutgers, The State University of New JerseyOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT04625517 | Performance of Contrast-Enhanced Spectral Mammography to Assess Neoadjuvant Chemotherapy Response (CEDM) | terminated | Phase 4 | 6 | University of Texas Southwestern Medical CenterOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT03190967 | T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery | terminated | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Oct 11, 2023 | clinicaltrials |
| NCT01873833 | Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer | terminated | Phase 2 | 10 | University of Southern CaliforniaOTHER | 1 | Oct 5, 2023 | clinicaltrials |
| NCT03916068 | Acute Post-Radiation Hyperbaric Oxygen (HBO2) for Breast Cancer Patients Who Have Recently Completed Radiation Therapy | terminated | Phase 2 | 1 | Legacy Health SystemOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT04139993 | RBX7455 Before Surgery for the Treatment of Operable Breast Cancer | terminated | Phase 1 | 3 | Mayo ClinicOTHER | 1 | Oct 4, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Feb 23, 2024source: clinicaltrials